Animal models of chronic obstructive pulmonary disease

被引:0
作者
Szelenyi, I [1 ]
Marx, D [1 ]
机构
[1] ASTA Med AG, Corp Res & Dev, Dept Pulm Pharmacol, Radebeul, Germany
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2001年 / 51卷 / 12期
关键词
animal models; chronic bronchitis; chronic obstructive pulmonary disease (COPD); emphysema; chronic obstructive pulmonary disease; animal model;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chronic obstructive pulmonary disease (COPD), which encompasses both chronic bronchitis and emphysema, is one of the most common respiratory conditions of adults in the developed world. Despite the high prevalence and enormous cost to healthcare and society, COPD has received scant attention In comparison to other respiratory conditions such as asthma and lung cancer. It is often thought of as a self-inflicted disease. But not all people who smoke develop COPD and not all patients with COPD are smokers. The causes of COPD are different. Its pathogenesis Is complex. There are very few effective treatments. Therefore, there is an urgent need to improve present therapy by drugs with new modes of actions. In contrast to many human diseases, chronic bronchitis and emphysema occur seldom in the animal world. Therefore, we have to mimic some characteristic features of these diseases In animals. For this reason, a wide variety of animal models have been developed and are employed In the search for new chemical entities for the treatment of COPD. In the present paper, the experimental models of COPD are critically reviewed.
引用
收藏
页码:1004 / 1014
页数:11
相关论文
共 117 条
[1]   A MODEL OF DECREASED FUNCTIONAL ALPHA-1-PROTEINASE INHIBITOR - PULMONARY PATHOLOGY OF DOGS EXPOSED TO CHLORAMINE-T [J].
ABRAMS, WR ;
COHEN, AB ;
DAMIANO, VV ;
ELIRAZ, A ;
KIMBEL, P ;
MERANZE, DR ;
WEINBAUM, G .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1132-1139
[2]  
ACHTERRATHTUCKERMANN U, 1992, LUNG, V170, P201
[3]  
ALBIN RJ, 1987, AM REV RESPIR DIS, V135, P1281
[4]   The effect of tasuldine, a bronchosecretolytic agent, on mucus rheology and clearability and the interaction with acetylcholine in ferrets [J].
App, EM ;
Tomkiewicz, RP ;
Hahn, HL ;
Engler, H ;
Vergin, H ;
King, M .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 1997, 10 (5-6) :271-276
[5]  
Behl C, 1997, J NEURAL TRANSM-SUPP, P125
[6]   RELEASE OF NEUTROPHIL PROTEINASE 4(3) AND LEUKOCYTE ELASTASE DURING PHAGOCYTOSIS AND THEIR INTERACTION WITH PROTEINASE-INHIBITORS [J].
BERGENFELDT, M ;
AXELSSON, L ;
OHLSSON, K .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1992, 52 (08) :823-829
[7]   Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema [J].
Betsuyaku, T ;
Nishimura, M ;
Takeyabu, K ;
Tanino, M ;
Venge, P ;
Xu, SY ;
Kawakami, Y .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (06) :1985-1991
[8]   CONTROL OF CACHECTIN (TUMOR-NECROSIS-FACTOR) SYNTHESIS - MECHANISMS OF ENDOTOXIN RESISTANCE [J].
BEUTLER, B ;
KROCHIN, N ;
MILSARK, IW ;
LUEDKE, C ;
CERAMI, A .
SCIENCE, 1986, 232 (4753) :977-980
[9]   Secretory leukoprotease inhibitor: Partnering alpha(1)-proteinase inhibitor to combat pulmonary inflammation [J].
Bingle, L ;
Tetley, TD .
THORAX, 1996, 51 (12) :1273-1274
[10]   MATRIX METALLOPROTEINASES - A REVIEW [J].
BIRKEDALHANSEN, H ;
MOORE, WGI ;
BODDEN, MK ;
WINDSOR, LJ ;
BIRKEDALHANSEN, B ;
DECARLO, A ;
ENGLER, JA .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250